Clinical Trial: Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral Prostatectomy

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT03912766) titled 'Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral Prostatectomy' on April 5.

Brief Summary: Hyponatremic hypovolemia is a frequent complication of transurethral resection of the prostate gland (TURP). Copeptin has been established as is a surrogate marker of vasopressin and is measured useful for thea clinical assessment of various sodium and water disturbances. The aim of our the study was to assess the utility of serum concentration of copeptin (CPP) and brain natriuretic peptide (NT-proBNP) for the prediction of postoperative alterations of serum sodium concentration. Study population comprised 43 pat...